News
DVAX
11.03
+1.66%
0.18
Weekly Report: what happened at DVAX last week (0902-0906)?
Weekly Report · 9h ago
Dynavax Technologies: Slow And Steady Wins The Race
Seeking Alpha · 3d ago
LANTHEUS APPOINTS JULIE EASTLAND AS NEW BOARD MEMBER
Reuters · 4d ago
LANTHEUS HOLDINGS : BOARD WILL BE COMPRISED OF TEN DIRECTORS
Reuters · 4d ago
Weekly Report: what happened at DVAX last week (0826-0830)?
Weekly Report · 09/02 09:28
Weekly Report: what happened at DVAX last week (0819-0823)?
Weekly Report · 08/26 09:27
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Seeking Alpha · 08/23 08:32
3 Biotech Names To Target Now
Seeking Alpha · 08/19 17:52
Weekly Report: what happened at DVAX last week (0812-0816)?
Weekly Report · 08/19 09:25
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Simply Wall St · 08/14 11:18
Weekly Report: what happened at DVAX last week (0805-0809)?
Weekly Report · 08/12 09:25
Assessing Dynavax Technologies: Insights From 4 Financial Analysts
Benzinga · 08/08 16:00
Dynavax Price Target Cut to $15.00/Share From $20.00 by Goldman Sachs
Dow Jones · 08/08 15:31
Dynavax Is Maintained at Neutral by Goldman Sachs
Dow Jones · 08/08 15:31
Goldman Sachs Maintains Neutral on Dynavax Technologies, Lowers Price Target to $15
Benzinga · 08/08 15:21
Dynavax Technologies (NASDAQ:DVAX) shareholders are still up 187% over 5 years despite pulling back 3.9% in the past week
Simply Wall St · 08/08 10:48
Dynavax Technologies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St · 08/08 10:42
HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target
Benzinga · 08/07 12:29
Dynavax Buy Rating Affirmed Despite Q2 Revenue Shortfall, Future Growth Anticipated
TipRanks · 08/07 10:43
Dynavax Stock Hold Rating Maintained Amidst Sales Uncertainty and Pipeline Risks
TipRanks · 08/07 07:46
More
Webull provides a variety of real-time DVAX stock news. You can receive the latest news about Dynavax Technolo through multiple platforms. This information may help you make smarter investment decisions.
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.